Eton Pharmaceuticals, Inc. (ETON) – What Are Researchers Thinking About This Stock?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $71.50.

Several analysts have recently weighed in on the stock. Craig Hallum reaffirmed a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a report on Thursday. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. B. Riley Financial reissued a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Finally, Canaccord Genuity Group raised their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $49.22 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The stock has a market capitalization of $1.41 billion, a P/E ratio of 129.53 and a beta of 0.90. The company’s fifty day moving average is $56.60 and its two-hundred day moving average is $41.46. Eton Pharmaceuticals has a 1 year low of $14.27 and a 1 year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. On average, sell-side analysts predict that Eton Pharmaceuticals will post 1.13 earnings per share for the current year.

Insider Activity at Eton Pharmaceuticals

In other news, insider David Krempa sold 25,000 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the transaction, the insider directly owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 79,166 shares of company stock worth $4,809,672 in the last quarter. 16.49% of the stock is currently owned by insiders.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. USA Financial Formulas acquired a new position in Eton Pharmaceuticals during the third quarter worth $62,000. Toth Financial Advisory Corp raised its position in Eton Pharmaceuticals by 41.7% in the third quarter. Toth Financial Advisory Corp now owns 1,700 shares of the company’s stock worth $88,000 after acquiring an additional 500 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Eton Pharmaceuticals in the second quarter valued at $2,156,000. HighTower Advisors LLC lifted its holdings in Eton Pharmaceuticals by 187.2% in the second quarter. HighTower Advisors LLC now owns 52,907 shares of the company’s stock valued at $1,915,000 after acquiring an additional 34,484 shares during the period. Finally, Sigma Planning Corp acquired a new stake in Eton Pharmaceuticals in the second quarter valued at $1,086,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.